Product Description
A novel BACE inhibitorÊ (Sourced from: https://www.diva-portal.org/smash/record.jsf?pid=diva2%3A687867&dswid=-2808)
Mechanisms of Action: BACE Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01462851 |
B3941001 | P1 |
Completed |
Healthy Volunteers |
2012-02-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|